SeaDrill Ltd. (SDRL) Financials Nov 14, 2014, 7:59

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
SeaDrill Ltd. (SDRL) Financials Nov 14, 2014, 7:59 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for SeaDrill Ltd.


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 3.25B 4.04B 4.19B 4.48B 5.28B
Cost of Goods Sold (COGS) incl. D&A 1.8B 2.26B 2.24B 2.44B 2.95B
COGS excluding D&A 1.41B 1.78B 1.68B 1.82B 2.23B
Depreciation & Amortization Expense 395.9M 479.8M 563M 615M 711M
Depreciation 395.9M 479.8M 563M 615M 711M
Amortization of Intangibles 0 - 0 0 -
Gross Income 1.45B 1.78B 1.95B 2.04B 2.34B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 149.1M 178.2M 202M 250M 300M
Research & Development - 0 0 0 0
Other SG&A 149.1M 178.2M 202M 250M 300M
Other Operating Expense 0 0 0 0 0
Unusual Expense (129.6M) 85.9M 356M (172M) (151M)
EBIT after Unusual Expense 129.6M (85.9M) (356M) 172M 151M
Non Operating Income/Expense 100.2M 39.6M 969M 9M 1.4B
Non-Operating Interest Income 78.1M 42.5M 21M 25M 24M
Equity in Affiliates (Pretax) 92.4M 47.8M (420M) (220M) (223M)
Interest Expense 228.4M 312.4M 295M 340M 445M
Gross Interest Expense 228.4M 312.4M 295M 416M 540M
Interest Capitalized 0 0 0 76M 95M
Pretax Income 1.47B 1.33B 1.67B 1.44B 2.94B
Income Tax 120M 159.3M 189M 232M 154M
Income Tax - Current Domestic - 0 0 0 0
Income Tax - Current Foreign - 184.2M 328M 167M 200M
Income Tax - Deferred Domestic - 0 0 0 0
Income Tax - Deferred Foreign - 13.7M 24M 58M (50M)
Income Tax Credits - 38.6M 163M (7M) (4M)
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 1.35B 1.17B 1.48B 1.21B 2.79B
Minority Interest Expense 91.9M 54.7M 81M 97M 133M
Net Income 1.26B 1.12B 1.4B 1.11B 2.65B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 1.26B 1.12B 1.4B 1.11B 2.65B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 1.26B 1.12B 1.4B 1.11B 2.65B
EPS (Basic) 3.16 2.73 3.05 2.36 5.66
Basic Shares Outstanding 398.5M 409.2M 459M 469M 469M
EPS (Diluted) 3.00 2.37 2.96 2.34 5.47
Diluted Shares Outstanding 436.8M 471.3M 488M 490M 492M
EBITDA 1.7B 2.08B 2.32B 2.41B 2.75B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth of Middle-Class Investors through Mutual Fund Ownership

Updated Category News Views 149

Mutual Funds and the Rise of the Middle-Class Investor Over recent years, mutual fund ownership has surged among middle-class families. According to insights from the Investment Company Institute (ICI), this trend signifies a vital transition as middle-income households increasingly seek investment opportunities. The growing presence of mutual funds in the American...

Continue Reading
Rques Exchange Reinforces Its Brand with Compliance Strategy

Updated Category News Views 180

Rques Exchange Reinforces Brand with Regulatory Frameworks Rques Exchange is taking significant steps to enhance its brand by emphasizing its commitment to regulatory alignment, operational transparency, and governance integrity in various markets. With global authorities increasingly scrutinizing digital asset platforms, Rques aims to position itself as a technology...

Continue Reading
Business Growth and Confidence: Provident Bank's Insights

Updated Category News Views 120

Increasing Business Confidence for the Future Recently, Provident Bank, a prominent financial institution based in New Jersey, conducted an enlightening Economic Outlook survey. This survey reflects the sentiments of 1,000 business leaders regarding the 2025 economic prospects. The results showcase a robust sense of optimism and confidence among businesses as they look...

Continue Reading
Performance Food Group Co: A Five-Year Stock Journey

Updated Category News Views 219

Unlocking the Value of Investment in Performance Food Group Co Performance Food Group Co (NYSE: PFGC) has delivered impressive returns over the last five years, standing out in the competitive market landscape. With an annualized return that has surpassed the market by 9.42%, investors have seen an average growth rate of around 24.5%. This stock is not just another entry...

Continue Reading
Understanding Rathbones Group Plc's Disclosure Requirements

Updated Category News Views 227

Key Information on Disclosure Requirements Understanding how companies disclose their shareholding is crucial for investors and stakeholders alike. Rathbones Group Plc plays an essential role in managing these disclosures, particularly regarding relevant securities that represent substantial interests in listed companies. Full Name of the Discloser The full name of the...

Continue Reading